Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE)

Critical Reviews in Oncology/Hematology

Volumn 64, Issue 2, 2007, Pages 106-114

  Blay, Jean Yves ^a   Koscielny, Serge ^b   Trédaniel, Jean ^c   Asselain, Bernard ^d   Goldwasser, François ^e   Misset, Jean Louis ^c   de Labareyre, Cécile ^f   Hagège, Charles ^g   Bismut, Hervé ^h   Marty, Michel ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT CURIE   (France)

^e Hôpital Cochin ^*  (France)

^f GLAXOSMITHKLINE   (France)

^g Léonard de Vinci Research Center   (France)

^h Strategik and Numerik   (France)

Author keywords

Chemotherapy; Composite index; Study design; Time related parameters

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TOPOTECAN;

BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OUTCOME ASSESSMENT; OVARY CANCER; PARAMETER; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; HUMANS; KINETICS; MODELS, THEORETICAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34848880453     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.04.013     Document Type: Review

References (30)

1. Therasse P. European Organisation for Research and Treatment of Cancer Data Center. Evaluation of response: new and standard criteria. Ann Oncol 13 Suppl 4 (2002) 127-129
2. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
3. van Glabbeke M., Verweij J., Judson I., Nielsen O.S., and EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38 4 (2002) 543-549
4. Estey E.H., and Thall P.F. New designs for phase 2 clinical trials. Blood 102 2 (2003) 442-448
5. Trédaniel J., Blay J.Y., Goldwasser F., et al. Decision making process in oncology practice: is the information available and what should it consist of?. Crit Rev Oncol Hematol 54 (2005) 165-170
6. Hemyari P. Robustness of the quartiles of survival time and survival probability. J Biopharm Stat 10 3 (2000) 299-318
7. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 9209 (2000) 1041-1047
8. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 12 (2002) 2812-2823
9. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 2 (2002) 92-98
10. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5 (2002) 20-28
11. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 1 (1996) 1-6
12. Fields A.L., and Runowicz C.D. Current therapies in ovarian cancer. Cancer Invest 21 1 (2003) 148-156
13. Gore M., ten Bokkel Huinink W., Carmichael J., et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19 7 (2001) 1893-1900
14. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 6 (1997) 2183-2193
15. Piccart M.J., Green J.A., Lacave A.J., et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer. A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18 6 (2000) 1193-1202
16. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 14 (2001) 3312-3322
17. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 10 (2000) 2095-2103
18. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
19. Cesano A., Lane S.R., Poulin R., Ross G., and Fields S.Z. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 15 6 (1999) 1233-1238
20. Varricchio C.G., and Sloan J.A. The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst 94 16 (2002) 1184-1185
21. Ferguson J.S., Summerhayes M., Masters S., Schey S., and Smith I.E. New treatments for advanced cancer: an approach to prioritization. Br J Cancer 83 10 (2000) 1268-1273
22. Exposito J., Hernandez J., Fernandez Feijoo A., Nieto T., and Briones E. New chemotherapy treatments in advanced cancer patients: an easily applicable evaluation of clinical efficacy and cost-effectiveness. Acta Oncol 42 8 (2003) 895-902
23. Cannistra S.A. The ethics of early stopping rules: who is protecting whom?. J Clin Oncol 22 9 (2004) 1542-1545
24. Chan S. Second-line chemotherapy for ovarian cancer. Lancet Oncol 4 6 (2003) 333-334
25. Gordon A.N., Tonda M., Sun S., and Rackoff W. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 1 (2004) 1-8
26. Trent J.C., Beach J., Burgess M.A., et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 98 12 (2003) 2693-2699
27. van Glabbeke M., Steward W., and Armand J.P. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?. Eur J Cancer 38 5 (2002) 635-638
28. Begg C., Cho M., Eastwood S., et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276 8 (1996) 637-639
29. Moher D., Schulz K.F., Altman D.G., and CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Clin Oral Invest 7 1 (2003) 2-7
30. Parulekar W.R., and Eisenhauer E.A. Novel endpoints and design of early clinical trials. Ann Oncol 13 Suppl 4 (2002) 139-143